🚀 Gate Square “Gate Fun Token Challenge” is Live!
Create tokens, engage, and earn — including trading fee rebates, graduation bonuses, and a $1,000 prize pool!
Join Now 👉 https://www.gate.com/campaigns/3145
💡 How to Participate:
1️⃣ Create Tokens: One-click token launch in [Square - Post]. Promote, grow your community, and earn rewards.
2️⃣ Engage: Post, like, comment, and share in token community to earn!
📦 Rewards Overview:
Creator Graduation Bonus: 50 GT
Trading Fee Rebate: The more trades, the more you earn
Token Creator Pool: Up to $50 USDT per user + $5 USDT for the first 50 launche
Zuo Li Pharmaceutical: The development work of Ling Yi Bio's Parkinson's pipeline LY-N001 is ongoing.
Jin10 data reported on September 7th that Zoli Pharmaceutical stated during an institutional survey that the research and development of Lingyi Bio's Parkinson's pipeline LY-N001 is continuing to advance, with the main preclinical research work already completed. This pipeline targets Parkinson's subtype patients associated with GBA1 gene mutations, with future goals of filing IND applications in China and the US and conducting clinical research as well as global market layout. Lingyi Bio is a company focused on the R&D of innovative drugs for single-gene genetic diseases, positioned to develop gene therapies with differentiated advantages. The company increased its investment in Lingyi Bio by 20 million yuan in April 2025.